Methods for treating monge's disease
AssigneeThe Regents of the University of California
InventorsGabriel G. Haddad, Priti Azad, Dan Zhou, Tariq M. Rana
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods of treating Monge's disease and/or reducing erythrocytosis in a subject that include: administering to the subject a therapeutic agent, wherein the therapeutic agent inhibits expression of a target gene, and wherein the therapeutic agent reduces erythrocytosis. Compositions include CK2 inhibitors and antisense nucleotides targeting IncRNAs.
Claims65
A method of treating Monge's disease in a subject, the method comprising:
- administering to the subject a therapeutic agent, wherein the therapeutic agent inhibits expression of a target gene, and wherein the therapeutic agent reduces erythrocytosis, thereby treating Monge's disease in the subject.
A method of reducing erythrocytosis in a subject, the method comprising:
- administering to the subject a therapeutic agent, wherein the therapeutic agent inhibits expression of a target gene, thereby reducing erythrocytosis in the subject.
A pharmaceutical composition comprising a therapeutic agent, wherein the therapeutic agent inhibits expression of a target gene and reduces erythrocytosis.
A pharmaceutical composition comprising a therapeutic agent, wherein the therapeutic agent inhibits expression of a target gene and reduces erythrocytosis, for use in the treatment of Monge's disease.
The use of a pharmaceutical composition comprising a therapeutic agent, in the manufacture of a medicament for treating Monge's disease, wherein the therapeutic agent inhibits expression of a target gene and reduces erythrocytosis.
Dependencies are inferred from the claim text.